☆ 4.7 Article

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype

EBIOMEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound

Kim N. Chi et al.

Summary: This study evaluated the utility of plasma-derived circulating tumor DNA (ctDNA) in identifying BRCA1, BRCA2, and ATM alterations in patients with metastatic castration-resistant prostate cancer. The results showed that ctDNA detection can complement tissue testing and serve as a valuable alternative for patients with no or insufficient tissue for genomic analyses.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Meeting Abstract Oncology

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

Xin Gao et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD) a multicentre, open-label, phase 2 trial

Matthew R. Smith et al.

Summary: This study evaluated the anti-tumor activity and safety of niraparib, a PARP inhibitor, in patients with metastatic castration-resistant prostate cancers and DNA repair gene defects (DRDs) who had previously failed treatment with an androgen signaling inhibitor and a taxane. The results showed that niraparib was well-tolerated and demonstrated anti-tumor activity in these patients, particularly in those with BRCA alterations.

LANCET ONCOLOGY (2022)

Add to Collection

Review Oncology

Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape

Rosario Prados-Carvajal et al.

Summary: PARP inhibitors have revolutionized the treatment of ovarian, breast, pancreatic, and prostate cancers but resistance to these drugs continues to be a challenge. In this review, the mechanisms of resistance to PARP inhibitors are discussed, with a focus on clinically relevant findings and potential strategies to overcome resistance.

CANCERS (2022)

Add to Collection

Article Multidisciplinary Sciences

Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer

Winston Tan et al.

Summary: Docetaxel chemotherapy is a standard treatment for mCRPC patients, but the genomic perturbations underlying resistance have not been fully characterized. The study found that RB1, TP53, and PTEN gene alterations were relatively modest during chemotherapy, potentially indicating the persistence of a clonal signature associated with treatment-induced lineage plasticity.

SCIENTIFIC REPORTS (2022)

Add to Collection

Review Urology & Nephrology

Genetics of neuroendocrine prostate cancer: recent progress in genetic understanding is translating into therapeutic opportunities

Gal Rinott Mizrahi et al.

Summary: This review article summarizes the new research advances in the understanding of the genetic and epigenetic aberrations underlying NEPC development and the new targeted therapeutic options developed based on NEPC genetics. NEPC is a highly aggressive malignancy with currently lack of effective treatments. However, ongoing clinical trials exploiting novel genetic and epigenetic alterations hold promise for improving clinical outcomes in NEPC.

CURRENT OPINION IN UROLOGY (2022)

Add to Collection

Article Oncology

Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers.

Melissa Lynne Johnson et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer

Kevin H. Kensler et al.

Summary: Carriers of germline BRCA2 pathogenic sequence variants have an increased risk of aggressive prostate cancer, and may benefit from precision oncology treatments. This study found distinct genomic alterations between BRCA2-deficient (BRCA2(d)) and BRCA2-intact (BRCA2(i)) prostate tumors, which are associated with etiological and prognostic differences.

NPJ PRECISION ONCOLOGY (2022)

Add to Collection

Article Oncology

Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer

Estefania Labanca et al.

Summary: This study found that FGFR1 expression plays an important role in bone metastasis of prostate cancer, and its activity enhanced bone metastasis and survival rate in mice, and the human samples also showed that FGFR1 were enriched in bone metastasis of castration-resistant prostate cancer. In addition, the study also found that the LAD1 protein co-expressed with FGFR1 plays an important role in the bone metastasis of prostate cancer.

EUROPEAN UROLOGY ONCOLOGY (2022)

Add to Collection

Article Oncology

Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer According to Somatic Damage DNA Repair Gene Alterations

Zoe Neviere et al.

Summary: This study aimed to evaluate the relationship between somatic DNA damage repair gene mutations and the response of mCRPC patients to standard therapies. The results showed that mCRPC patients with BRCA1/2 and ATM mutations had a longer response to standard therapies.

CURRENT ONCOLOGY (2022)

Add to Collection

Article Urology & Nephrology

Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer

Heidi Fettke et al.

Summary: Measuring changes in total cell-free DNA levels in plasma can help predict how patients with metastatic prostate cancer will respond to different treatments. Higher levels or changes in cfDNA concentration may be associated with worse treatment outcomes, but in some cases, an increase in total cfDNA levels may correlate with better efficacy.

EUROPEAN UROLOGY FOCUS (2021)

Add to Collection

Article Oncology

BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression

Evan Warner et al.

Summary: The study identifies BRCA2, ATM, and CDK12 as the most frequently disrupted DDR genes in ctDNA of metastatic prostate cancer patients, collectively mutated in 15% of cases. ATM defects and TP53 mutations were rare, with most patients showing biallelic gene disruption. Loss of BRCA2 and CDK12, but not ATM, was associated with poor clinical outcomes.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms

Hanna Tukachinsky et al.

Summary: Comprehensive genomic profiling (CGP) of cell-free circulating tumor DNA (ctDNA) is a promising approach for patients with metastatic castration-resistant prostate cancer (mCRPC), providing a minimally invasive alternative for detecting targetable genomic alterations. Analysis of ctDNA revealed a high concordance with tissue-based CGP, particularly in detecting BRCA1/2 mutations, while also identifying additional acquired resistance alterations. This highlights the potential of ctDNA as a clinical complement to tissue CGP, with reflex to tissue CGP in case of negative actionable variants.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor

Mariia Radaeva et al.

Summary: The research focused on further developing small molecule inhibitors of AR DBD dimerization and demonstrated their improved biological activity in various assays, including mammalian two-hybrid analysis, inhibition of AR-V7 transcriptional activity, and enhanced microsomal stability. These findings provide a foundation for the development of AR inhibitors with entirely novel mechanisms of action.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Oncology

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program

Dae-Hwan Kim et al.

Summary: NEPC is the most aggressive lineage plasticity in prostate cancer, with limited treatment options. By inhibiting AR and using BET inhibitors, it is possible to block this lineage plasticity, showing promising potential for t-NEPC treatment.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1) an-label, 2 trial

Johann S. de Bono et al.

Summary: Talazoparib demonstrated durable antitumour activity in advanced metastatic castration-resistant prostate cancers with DDR-HRR gene alterations, supporting further investigation in larger, randomised clinical trials.

LANCET ONCOLOGY (2021)

Add to Collection

Article Endocrinology & Metabolism

Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer

Heidi Fettke et al.

Summary: The study found that variations in NCOA2 can impact patients' survival rates and treatment responses in metastatic castration-resistant prostate cancer (mCRPC), especially in relation to variations in the AR pathway. This helps to better understand treatment strategies and prognosis for mCRPC, and further research is needed to determine if NCOA2 variations could serve as markers of resistance to AR pathway inhibitors.

PROSTATE (2021)

Add to Collection

Article Oncology

Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer

Edmond M. Kwan et al.

Summary: CNVs in the PTEN-PI3K-AKT pathway were readily detected using a novel cfDNA assay in mCRPC patients, with high prevalence of PTEN loss and PIK3CA gain. Additional PTEN-PI3K-AKT pathway aberrations were found in one fifth of PTEN-neutral cases, and concurrent CNVs in the PTEN-PI3K-AKT and AR pathways predicted poor survival outcomes, suggesting potential benefits of dual AR/Akt inhibition in precision treatment for mCRPC.

JCO PRECISION ONCOLOGY (2021)

Add to Collection

Article Oncology

Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer

Elie Ritch et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression

Goutam Chakraborty et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Next-generation sequencing (NGS) of tumor tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC): The PROfound phase III study experience.

Maha H. A. Hussain et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Joaquin Mateo et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Urology & Nephrology

Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer

Heidi Fettke et al.

EUROPEAN UROLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

Manish Kohli et al.

EBIOMEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Olaparib for Metastatic Castration-Resistant Prostate Cancer

J. de Bono et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

Wassim Abida et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Maha Hussain et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Letter Oncology

Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer

Bram De Laere et al.

JAMA ONCOLOGY (2019)

Add to Collection

Article Multidisciplinary Sciences

Tumour lineage shapes BRCA-mediated phenotypes

Philip Jonsson et al.

NATURE (2019)

Add to Collection

Article Urology & Nephrology

Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer

Gillian Vandekerkhove et al.

EUROPEAN UROLOGY (2019)

Add to Collection

Article Oncology

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer

Elena Castro et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Review Oncology

Cell-free DNA in cancer: current insights

Heidi Fettke et al.

CELLULAR ONCOLOGY (2019)

Add to Collection

Article Oncology

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases

Heini M. L. Kallio et al.

BRITISH JOURNAL OF CANCER (2018)

Add to Collection

Article Urology & Nephrology

Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide

Emmanuel S. Antonarakis et al.

EUROPEAN UROLOGY (2018)

Add to Collection

Article Oncology

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012

Maha Hussain et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

Matti Annala et al.

CANCER DISCOVERY (2018)

Add to Collection

Correction Biochemistry & Molecular Biology

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (vol 174, pg 758, 2018)

David A. Quigley et al.

CELL (2018)

Add to Collection

Article Oncology

SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

Gunther Boysen et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Article Urology & Nephrology

Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer

Matti Annala et al.

EUROPEAN UROLOGY (2017)

Add to Collection

Article Multidisciplinary Sciences

Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors

Viktor A. Adalsteinsson et al.

NATURE COMMUNICATIONS (2017)

Add to Collection

Article Multidisciplinary Sciences

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer

Mohammad Asim et al.

NATURE COMMUNICATIONS (2017)

Add to Collection

Article Multidisciplinary Sciences

Mutations in BRCA2 and taxane resistance in prostate cancer

Cathleen Nientiedt et al.

SCIENTIFIC REPORTS (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Integrative Clinical Genomics of Advanced Prostate Cancer

Dan Robinson et al.

CELL (2015)

Add to Collection

Article Oncology

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

Arun A. Azad et al.

CLINICAL CANCER RESEARCH (2015)

Add to Collection

Article Medicine, Research & Experimental

An androgen receptor N-terminal domain antagonist for treating prostate cancer

Jae-Kyung Myung et al.

JOURNAL OF CLINICAL INVESTIGATION (2013)

Add to Collection

Article Genetics & Heredity

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

Christopher E. Barbieri et al.

NATURE GENETICS (2012)

Add to Collection

Article Multidisciplinary Sciences

Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells

JTE Lim et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.